Avis Budget Group, Inc. logo

Avis Budget Group, Inc. (CAR)

Market Closed
21 Jul, 20:00
NASDAQ (NGS) NASDAQ (NGS)
$
162. 24
+2.72
+1.7051%
After Hours
$
170. 00
+7.76 +4.783%
5.64B Market Cap
4.27 P/E Ratio
40% Div Yield
1.36M Volume
39.99 Eps
$ 159.52
Previous Close
Add Transaction
Day Range
158.22 163.13
Year Range
85.96 847.7
Want to track CAR and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Anixa Biosciences: Oncology Platform With Asymmetric Upside

Anixa Biosciences: Oncology Platform With Asymmetric Upside

ANIX has a dual-platform approach. It has an FSHR‑targeted CAR‑T program for ovarian cancer and an α‑lactalbumin breast cancer vaccine. Their Phase 1 CAR‑T showed reasonable safety, as one patient remains alive after 24 months. Others have also exceeded the four‑month median survival. This means ANIX could start testing even higher doses, which might be even more effective.

Seekingalpha | 1 year ago
Meme stocks back with a bang as investors pile into these 2 names

Meme stocks back with a bang as investors pile into these 2 names

The meme-stock frenzy is seemingly making a comeback in 2025 as investors once again chase unprofitable companies for their latest bets.

Finbold | 1 year ago
Canadian Apartment Properties: Not The Cheapest, But Still A Buy

Canadian Apartment Properties: Not The Cheapest, But Still A Buy

Canadian residential real estate offers overlooked opportunities for US investors amid shifting immigration trends. CAPREIT is a well-established REIT with stable occupancy, rising rents, and a solid 3.5% dividend yield backed by a 60% payout ratio and over 5% AFFO yield. Technical analysis shows no short-term price catalyst, but long-term dividend yield trends signal potential upside unless major negative events occur.

Seekingalpha | 1 year ago
Gilead's CAR-T cell therapy shows promise in deadly brain cancer

Gilead's CAR-T cell therapy shows promise in deadly brain cancer

A Gilead Sciences-backed therapy made with a patient's own white blood cells shrank tumors in 62% of patients with recurrent glioblastoma, a rare event for a fatal brain cancer with few treatment options, researchers reported on Sunday.

Reuters | 1 year ago
Avis Budget: Used Car Optimism Is Priced In (Downgrade)

Avis Budget: Used Car Optimism Is Priced In (Downgrade)

Avis has rallied over 60% since my March buy call, driven by strong used car pricing and tariff tailwinds, now reaching my $100-$120 price target. Q1 results were weak due to soft commercial demand, but leisure bookings are improving; cost cuts and fleet reductions are helping utilization and margins. Avis's upside is highly levered to used car prices, but current valuation already reflects a 20% gain in residual values and optimistic scenarios.

Seekingalpha | 1 year ago
Canadian Apartment Properties: Stable Fundamentals But Lacking Clear Upside Catalysts

Canadian Apartment Properties: Stable Fundamentals But Lacking Clear Upside Catalysts

Canadian Apartment Properties REIT's Q1 2025 showed high occupancy at 97.6%, despite a slight year-over-year decrease and a significant 26% increase in average monthly rent. NOI margin dropped to 62.4% due to higher utilities and taxes, but improvements are expected with the recent carbon tax removal. Growth in rent increases has slowed, with a weighted average change of 3.4% compared to 4.1% in 2024.

Seekingalpha | 1 year ago
Avis Budget Stock Price Increases 6% Since Reporting Loss in Q1

Avis Budget Stock Price Increases 6% Since Reporting Loss in Q1

The decline in revenues in the Americas hurts CAR's top line in the first quarter of 2025.

Zacks | 1 year ago
Avis Budget Group, Inc. (CAR) Q1 2025 Earnings Call Transcript

Avis Budget Group, Inc. (CAR) Q1 2025 Earnings Call Transcript

Avis Budget Group, Inc. (NASDAQ:CAR ) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants David Calabria - Senior Vice President, Corporate Finance and Treasurer Joe Ferraro - President and Chief Executive Officer Izzy Martins - Executive Vice President and Chief Financial Officer Conference Call Participants John Babcock - Bank of America Stephanie Moore - Jefferies Christoper Stathoulopoulos - Susquehanna International Group, LLP Joseph Padua - JPMorgan Chase Dan Levy - Barclays Lizzie Dove - Goldman Sachs Chris Woronka - Deutsche Bank Operator Greetings, and welcome to the Avis Budget Group's First Quarter 2025 Earnings Conference Call. At this time, all participants will be in listen-only mode.

Seekingalpha | 1 year ago
Compared to Estimates, Avis Budget (CAR) Q1 Earnings: A Look at Key Metrics

Compared to Estimates, Avis Budget (CAR) Q1 Earnings: A Look at Key Metrics

The headline numbers for Avis Budget (CAR) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks | 1 year ago
Avis Budget Group (CAR) Reports Q1 Loss, Lags Revenue Estimates

Avis Budget Group (CAR) Reports Q1 Loss, Lags Revenue Estimates

Avis Budget Group (CAR) came out with a quarterly loss of $14.35 per share versus the Zacks Consensus Estimate of a loss of $5.72. This compares to loss of $3.21 per share a year ago.

Zacks | 1 year ago
Earnings Preview: Avis Budget Group (CAR) Q1 Earnings Expected to Decline

Earnings Preview: Avis Budget Group (CAR) Q1 Earnings Expected to Decline

Avis Budget (CAR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks | 1 year ago
CAR Benefits From Demand in North America Despite Rising Fleet Costs

CAR Benefits From Demand in North America Despite Rising Fleet Costs

Avis Budget Group's stock is benefiting from strategic fleet management, enabling it to deal with a turbulent supply chain.

Zacks | 1 year ago
Loading...
Load More